Schering-Plough reports encouraging results from Phase II hepatitis trial
In part I of the study, a 48-week boceprevir regimen achieved a 75% sustained virologic response (SVR) rate (n=77/103) in patients who received four weeks of Pegintron and
Jazz Pharmaceuticals and AbCellera have signed a preclinical research, option, and licence agreement for the discovery and development of T-cell-engaging multispecific antibodies, or T-cell engagers (TCEs), for gastrointestinal (GI) cancers and other solid tumours.